hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors

Carcinogenesis

Volumn 34, Issue 7, 2013, Pages 1458-1467

  Xiao, Ziwei ^a,b   Ko, Hui Ling ^a   Goh, Ee Hui ^a   Wang, Bei ^a   Ren, Ee Chee ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; FLICE INHIBITORY PROTEIN; FLUOROURACIL; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BID; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MESSENGER RNA SYNTHESIS; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL SURVIVAL; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEP G2 CELLS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HUMANS; LIVER NEOPLASMS; MUTAGENESIS, SITE-DIRECTED; PROTEOLYSIS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84880266961     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt085     Document Type: Article

References (54)

1. Dreyfuss, G. et al. (1993) hnRNP proteins and the biogenesis of mRNA. Annu. Rev. Biochem., 62, 289-321.
2. Bomsztyk, K. et al. (2004) hnRNP K: one protein multiple processes. Bioessays, 26, 629-638.
3. Barboro, P. et al. (2009) Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br. J. Cancer, 100, 1608-1616.
4. Carpenter, B. et al. (2006) Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br. J. Cancer, 95, 921-927.
5. Mandal, M. et al. (2001) Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem., 276, 9699-9704.
6. Perrotti, D. et al. (2007) From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin. Cancer Res., 13, 1638-1642.
7. Pino, I. et al. (2003) Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer, 41, 131-143.
8. Zhou, R. et al. (2010) Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Int. J. Cancer, 126, 395-404.
9. Chen, L.C. et al. (2008) Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin. Cancer Res., 14, 3807-3813.
10. Matta, A. et al. (2009) Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int. J. Cancer, 125, 1398-1406.
11. Inoue, A. et al. (2007) Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc. Natl Acad. Sci. U.S.A., 104, 8983-8988.
12. Ritchie, S.A. et al. (2003) Identification of the SRC pyrimidine-binding protein (SPy) as hnRNP K: implications in the regulation of SRC1A transcription. Nucleic Acids Res., 31, 1502-1513.
13. Takimoto, M. et al. (1993) Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J. Biol. Chem., 268, 18249-18258.
14. Lacroix, L. et al. (2000) Identification of two human nuclear proteins that recognise the cytosine-rich strand of human telomeres in vitro. Nucleic Acids Res., 28, 1564-1575.
15. Moumen, A. et al. (2005) hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell, 123, 1065-1078.
16. Chen, L.C. et al. (2010) The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ., 17, 1463-1473.
17. Gao, F.H. et al. (2009) Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp. Cell Res., 315, 3250-3258.
18. White, M.C. et al. (2010) Inactivation of hnRNP K by expanded intronic AUUCU repeat induces apoptosis via translocation of PKCdelta to mitochondria in spinocerebellar ataxia 10. PLoS Genet., 6, e1000984.
19. van Domselaar, R. et al. (2012) All human granzymes target hnRNP K that is essential for tumor cell viability. J. Biol. Chem., 287, 22854-22864.
20. van Domselaar, R. et al. (2012) Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication. Cell Death Differ., 20, 419-429.
21. Pop, C. et al. (2009) Human caspases: activation, specificity, and regulation. J. Biol. Chem., 284, 21777-21781.
22. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
23. Wong, R.S. (2011) Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. Cancer Res., 30, 87.
24. El-Serag, H.B. et al. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576.
25. Fabregat, I. (2009) Dysregulation of apoptosis in hepatocellular carcinoma cells. World J. Gastroenterol., 15, 513-520.
26. Blanc, J.F. et al. (2005) Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics, 5, 3778-3789.
27. Kim, W. et al. (2003) Comparison of proteome between hepatitis B virusand hepatitis C virus-associated hepatocellular carcinoma. Clin. Cancer Res., 9, 5493-5500.
28. Ostrowski, J. et al. (2003) Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br. J. Cancer, 89, 1493-1501.
29. Guo, Y. et al. (2012) Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J. Hematol. Oncol., 5, 37.
30. Ng, L.F. et al. (2005) Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication. PLoS Med., 2, e163.
31. Hsieh, T.Y. et al. (1998) Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. J. Biol. Chem., 273, 17651-17659.
32. Marin, J.J. et al. (2008) Chemotherapy in the treatment of primary liver tumours. Cancer Ther., 6, 711-728.
33. Zhang, P. et al. (2010) HnRNP K and PDI marked response to chemotherapy to human colorectal cancer cells. Electrophoresis, 31, 1731-1738.
34. Longley, D.B. et al. (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 3, 330-338.
35. Mirza, A. et al. (2003) Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene, 22, 3645-3654.
36. Rahman-Roblick, R. et al. (2007) p53 targets identified by protein expression profiling. Proc. Natl Acad. Sci. U.S.A., 104, 5401-5406.
37. Backus, H.H. et al. (2003) Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur. J. Cancer, 39, 1310-1317.
38. Dix, M.M. et al. (2008) Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell, 134, 679-691.
39. Mahrus, S. et al. (2008) Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell, 134, 866-876.
40. Ashkenazi, A. (2008) Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev., 19, 325-331.
41. Wang, S. (2008) The promise of cancer therapeutics targeting the TNFrelated apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene, 27, 6207-6215.
42. Li, H. et al. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94, 491-501.
43. Shiozaki, E.N. et al. (2004) Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem. Sci., 29, 486-494.
44. Petitjean, A. et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat., 28, 622-629.
45. Notarbartolo, M. et al. (2004) Expression of IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells. Ann. N. Y. Acad. Sci., 1028, 289-293.
46. Shiraki, K. et al. (2003) Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int. J. Mol. Med., 12, 705-708.
47. Vischioni, B. et al. (2006) Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum. Pathol., 37, 78-86.
48. Jost, P.J. et al. (2009) XIAP discriminates between type I and type II FASinduced apoptosis. Nature, 460, 1035-1039.
49. Okano, H. et al. (2003) Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab. Invest., 83, 1033-1043.
50. Wang, X.W. et al. (2002) Molecular pathogenesis of human hepatocellular carcinoma. Toxicology, 181-182, 43-47.
51. Enge, M. et al. (2009) MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell, 15, 171-183.
52. Benelli, R. et al. (2009) Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int. J. Cancer, 124, 2989-2996.
53. Liu, H.C. et al. (2006) 5-Fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. Cancer J., 12, 482-493.
54. Kimura, E. et al. (2003) Heterogeneous nuclear ribonucleoprotein K interacts with and is proteolyzed by calpain in vivo. Biosci. Biotechnol. Biochem., 67, 1786-1796.